Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Alvotech
< Previous
1
2
3
Next >
Alvotech to Participate in Morgan Stanley Annual Sustainable Finance Summit
May 17, 2023
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech Issues Annual Equality Report Covering 2022
May 15, 2023
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech enters into commercialization agreement with Polifarma for proposed biosimilar to Eylea® (aflibercept)
May 10, 2023
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech Initiates Confirmatory Patient Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria®
May 04, 2023
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech to Report First Quarter 2023 Financial Results and Recent Business Highlights on May 18, 2023 and Host Conference Call on May 19, 2023 at 8:00 am ET
May 03, 2023
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Sarah Tanksley Joins Board of Directors for Alvotech hf. and Sandra Casaca Appointed Chief Quality Officer
April 19, 2023
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech Provides Regulatory Update on AVT02 Biologics License Application
April 13, 2023
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech Provides Update on Corporate Sustainability Framework
March 28, 2023
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech to Present Clinical Study Data for AVT04, a Proposed Biosimilar to Stelara®, at 2023 American Academy of Dermatology (AAD) Annual Meeting
March 17, 2023
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech Reports Financial Results for Full Year 2022 and Provides Business Update
March 01, 2023
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech Announces Webcast of 2022 Full Year Financial Results at 8:00 am ET on March 2, 2023
February 27, 2023
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Settlement of Alvotech Private Share Placement Completed
February 10, 2023
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
EMA Confirms Acceptance of Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)
February 09, 2023
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech Enters Into Commercialization Agreement With Advanz Pharma for Proposed Biosimilar to Xolair® (Omalizumab)
February 06, 2023
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech and Bioventure Announce Approval of AVT02 (adalimumab) as Simlandi in Saudi Arabia
January 24, 2023
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech Completes $137 Million Private Share Placement
January 23, 2023
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech and Fuji Pharma Expand Partnership Adding a New Biosimilar Candidate
January 13, 2023
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech Initiates Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria®
January 11, 2023
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech and Teva Announce Acceptance of U.S. Biologics License Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)
January 06, 2023
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
TEVA
Update on U.S. Regulatory Status of AVT02, Alvotech’s Proposed High-Concentration, Interchangeable Biosimilar to Humira®
December 22, 2022
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
TEVA
Correction to Total Amount in Announcement About Private Placement Published 2022-12-16 09:00 GMT to headline field
December 16, 2022
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech Completes $59.7 Million Private Placement
December 16, 2022
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech Shares Start Trading on Nasdaq Iceland Main Market
December 08, 2022
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech and STADA Broaden Access to Hukyndra® adalimumab biosimilar in Europe
December 07, 2022
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech Announces Changes to its Leadership Team
December 01, 2022
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech Secures Financing Facilities of Approximately $136 Million
November 16, 2022
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech Reports Financial Results for First Nine Months of 2022 And Provides Business Update
November 16, 2022
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech Announces Australian Marketing Authorization for AVT02, a Biosimilar to Humira®
November 14, 2022
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech to Present Switching Study Data for AVT02, a Proposed Biosimilar to Humira®, at 2022 American College of Rheumatology Conference
November 10, 2022
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech to Report First Nine Months Financial Results on November 15, 2022 and Host Business Update Conference Call at 8:00 am ET on November 16, 2022
October 27, 2022
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.